5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

Seeking Alpha • Sep 18, 2026

iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?

iShares U.S. Healthcare ETF offers a more diversified portfolio and lower expense ratio than Invesco Biotechnology & Genome ETF. Invesco Biotechnology & Genome ETF delivered a higher 1-year total return but has experienced significantly larger historical drawdowns.

The Motley Fool • Sep 9, 2026

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios and strong R&D pipelines, are better positioned to offset looming patent cliffs.

Seeking Alpha • Sep 8, 2026

Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs

Nine of the 16 Big Pharma stocks covered in this article set new 52-week highs during August, reflecting strong momentum across the sector. Also, the rally has been driven by strong Q2 results, as well as Wall Street's growing shift toward healthcare amid continued geopolitical tensions in the Middle East.

Seeking Alpha • Aug 31, 2026

Should You Invest in the iShares U.S. Healthcare ETF (IYH)?

Looking for broad exposure to the Healthcare - Broad segment of the equity market? You should consider the iShares U.S. Healthcare ETF (IYH), a passively managed exchange traded fund launched on June 12, 2000.

Zacks Investment Research • Aug 24, 2026

PPH vs. IYH: Which Healthcare Fund Is the Better Buy?

The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides broad exposure across the healthcare sector, whereas the VanEck Pharmaceutical ETF (NYSEMKT:PPH) concentrates specifically on pharmaceutical stocks. PPH offers a slightly lower expense ratio and a higher dividend yield than IYH.

The Motley Fool • Aug 18, 2026

IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play?

The iShares U.S. Healthcare ETF provides broad sector exposure with 100 holdings, while the First Trust NYSE Arca Biotechnology Index Fund focuses on a concentrated basket of 30 biotech stocks. The First Trust fund has delivered higher recent returns but experiences greater price volatility.

The Motley Fool • Aug 13, 2026

Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now?

Simplify Health Care ETF has significantly outperformed iShares U.S. Healthcare ETF on a 1-year total return basis. iShares U.S. Healthcare ETF offers a lower expense ratio and a higher trailing-12-month dividend yield.

The Motley Fool • Aug 13, 2026

Health Care Shakes Off A 5-Day Slide

Health Care ended a five-day losing streak on Wednesday with a 1.34% rally. The streak tied the five days ending June 18 for the sector's longest of 2026.

Seeking Alpha • Aug 7, 2026

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit?

Fidelity MSCI Health Care Index ETF carries a significantly lower expense ratio of 0.08% compared to 0.38% for iShares U.S. Healthcare ETF Fidelity MSCI Health Care Index ETF provides broader exposure with 334 holdings, while iShares U.S. Healthcare ETF is more concentrated with 100 positions Both funds exhibit similar risk profiles with five-year maximum drawdowns near 18% and nearly identical beta measurements

The Motley Fool • Aug 1, 2026